ReviewWorld journal of clinical cases2026
Atherogenic index of plasma in stroke: A comprehensive review of its diagnostic, prognostic, and pathophysiological significance.
Review in World journal of clinical cases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oxidative dyslipidemia in early pregnancy: integrating atherogenic index of plasma (AIP) and uric acid (UA) to refine preeclampsia risk stratification.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The atherogenic index of plasma (AIP), defined as log [triglycerides (TG)/high-density lipoprotein cholesterol], an emerging lipid-based biomarker reflecting circulating TG and high-density lipoprotein cholesterol levels, has been associated with metabolic syndrome, coronary heart disease, and atherosclerosis. Its role in cardiovascular disease has been well established, yet there is growing interest in its application in cerebrovascular conditions, particularly stroke. Stroke is one of the leading causes of death and disability worldwide; hence, there is a need for integrative biomarkers to help improve risk prediction and accuracy of prognostication. Recent studies suggest that elevated AIP is independently associated with stroke incidence, especially among individuals with diabetes, prediabetes, and metabolic syndrome. Higher AIP levels have been associated with worse stroke severity at presentation, a higher risk of early neurological deterioration, and worse short-term outcomes. This is likely a consequence of AIP indicating vascular inflammation, endothelial dysfunction, and intracranial atherosclerosis. In observational studies, AIP has demonstrated comparable or stronger associations than other markers of insulin resistance, such as the TG-glucose index and the Chinese Visceral Adiposity Index, in specific metabolic populations. It is a low-cost and easily available biomarker, making it useful in primary prevention clinics, stroke units, and for managing metabolic syndrome. Given the increasing number of observational studies and population-based data, a comprehensive synthesis is needed to evaluate AIP's diagnostic, prognostic, and pathophysiological significance in stroke. This narrative review consolidates current findings on AIP's relevance in ischemic stroke and explores its potential integration into stroke risk stratification. Existing evidence is largely observational in nature, limiting causal interpretation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.